This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (257)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Adherence  • Alert me on articles by topic

A Cross-National Study

Jerry Avorn, MD; Johanne Monette, MD, MSc; Anne Lacour, PhD; Rhonda L. Bohn, MPH; Mark Monane, MD, MS; Helen Mogun, MS; Jacques LeLorier, MD, PhD

JAMA. 1998;279:1458-1462.

Context.— Although clinical trials have demonstrated the benefits of lipid-lowering therapy, little is known about how these drugs are prescribed or used in the general population.

Objective.— To estimate predictors of persistence with therapy for lipid-lowering drug regimens in typical populations of patients in the United States and Canada.

Design.— A cohort study defining all prescriptions filled for lipid-lowering drugs during 1 year, as well as patients' demographic and clinical characteristics.

Setting.— New Jersey's Medicaid and Pharmacy Assistance for the Aged and Disabled programs and Quebec's provincial medical care program.

Patients.— All continuously enrolled patients older than 65 years who filled 1 or more prescriptions for lipid-lowering drugs (N=5611 in the US programs, and N = 1676 drawn from a 10% sample in Quebec).

Main Outcome Measures.— Proportion of days during the study year for which patients had filled prescriptions for lipid-lowering drugs; predictors of good vs poor persistence with therapy.

Results.— In both populations, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year. Persistence rates with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were significantly higher than those seen with cholestyramine (64.3% vs 36.6% of days with drug available, respectively). Patients with hypertension, diabetes, or coronary artery disease had significantly higher rates of persistence with lipid-lowering regimens. In New Jersey, multivariable analysis indicated that the poorest patients (those enrolled in Medicaid) had lower rates of drug use than less indigent patients (those enrolled in Pharmacy Assistance for the Aged and Disabled) after adjusting for possible confounders, despite virtually complete drug coverage in both programs. When rates of use were measured in the US population for the 5 years following the study year, only 52% of surviving patients who were initially prescribed lipid-lowering drugs were still filling prescriptions for this drug class.

Conclusion.— In all populations studied, patients who were prescribed lipid-lowering drug regimens remained without filled prescriptions for over a third of the study year on average. Rates of persistence varied substantially with choice of agent prescribed, comorbidity, and socioeconomic status, despite universal coverage of prescription drug costs. After 5 years, about half of the surviving original cohort in the United States had stopped using lipid-lowering therapy altogether.

From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Drs Avorn, Monette, and Monane and Mss Bohn and Mogun); and the Centre de Recherche, Hôtel-Dieu de Montréal, Université de Montréal, Montreal, Quebec (Drs Lacour and LeLorier).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of Topical Cyclosporine for the Treatment of Dry Eye Disease
Perry et al.
Arch Ophthalmol 2008;126:1046-1050.
ABSTRACT | FULL TEXT  

Cardiovascular Risk Education and Social Support (CaRESS): Report of a Randomized Controlled Trial from the Kentucky Ambulatory Network (KAN)
Pearce et al.
J Am Board Fam Med 2008;21:269-281.
ABSTRACT | FULL TEXT  

Do patients' expectations influence their use of medications?: Qualitative study
Dolovich et al.
cfp 2008;54:384-393.
ABSTRACT | FULL TEXT  

Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction
Jackevicius et al.
Circulation 2008;117:1028-1036.
ABSTRACT | FULL TEXT  

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge et al.
JCO 2008;26:556-562.
ABSTRACT | FULL TEXT  

Family practice patients' adherence to statin medications
Natarajan et al.
cfp 2007;53:2144-2145.
ABSTRACT | FULL TEXT  

Use of statins and beta-blockers after acute myocardial infarction according to income and education
Rasmussen et al.
J. Epidemiol. Community Health 2007;61:1091-1097.
ABSTRACT | FULL TEXT  

Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy: The CHECK-UP Study: A Randomized Controlled Trial
Grover et al.
Arch Intern Med 2007;167:2296-2303.
ABSTRACT | FULL TEXT  

Factors Related to Adherence to Statin Therapy
McGinnis et al.
The Annals of Pharmacotherapy 2007;41:1805-1811.
ABSTRACT | FULL TEXT  

Statin Protection Against Influenza and COPD Mortality
Fedson and Frost
Chest 2007;132:1406-1407.
FULL TEXT  

Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities
Gnavi et al.
Eur J Public Health 2007;17:492-496.
ABSTRACT | FULL TEXT  

Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients
Bonovas et al.
JCO 2007;25:3462-3468.
ABSTRACT | FULL TEXT  

How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials
Schedlbauer et al.
Fam Pract 2007;24:380-387.
ABSTRACT | FULL TEXT  

Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review
Shrank et al.
The Annals of Pharmacotherapy 2007;41:783-801.
ABSTRACT | FULL TEXT  

Leading the Elephant Out of the Corner: The Future of Health Care: Presidential Address at the American Heart Association 2006 Scientific Sessions
Gibbons
Circulation 2007;115:2221-2230.
FULL TEXT  

Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment
Schneeweiss et al.
Circulation 2007;115:2128-2135.
ABSTRACT | FULL TEXT  

Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Setoguchi et al.
Circulation 2007;115:27-33.
ABSTRACT | FULL TEXT  

Potentially Unintended Discontinuation of Long-term Medication Use After Elective Surgical Procedures
Bell et al.
Arch Intern Med 2006;166:2525-2531.
ABSTRACT | FULL TEXT  

Influence of socioeconomic status on clinical outcomes and quality of life after percutaneous coronary intervention.
Denvir et al.
J. Epidemiol. Community Health 2006;60:1085-1088.
ABSTRACT | FULL TEXT  

Statin use in American Indians and Alaska Natives with coronary artery disease.
Cooke et al.
Am J Health Syst Pharm 2006;63:1717-1722.
ABSTRACT | FULL TEXT  

Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended-Release Niacin
LaFleur et al.
The Annals of Pharmacotherapy 2006;40:1274-1279.
ABSTRACT | FULL TEXT  

Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
Gislason et al.
Eur Heart J 2006;27:1153-1158.
ABSTRACT | FULL TEXT  

The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Shrank et al.
Arch Intern Med 2006;166:332-337.
ABSTRACT | FULL TEXT  

Non-adherence to endocrine therapy for breast cancer
Partridge
Ann Oncol 2006;17:183-184.
FULL TEXT  

Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT | FULL TEXT  

Compliance With Osteoporosis Medications
Solomon et al.
Arch Intern Med 2005;165:2414-2419.
ABSTRACT | FULL TEXT  

Combination Pharmacotherapy for Cardiovascular Disease
Combination Pharmacotherapy and Public Health Rese
ANN INTERN MED 2005;143:593-599.
ABSTRACT | FULL TEXT  

Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy
Benner et al.
Am J Health Syst Pharm 2005;62:1468-1475.
ABSTRACT | FULL TEXT  

Over-the-Counter Statins
Choudhry and Avorn
ANN INTERN MED 2005;142:910-913.
ABSTRACT | FULL TEXT  

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman et al.
Arch Intern Med 2005;165:1147-1152.
ABSTRACT | FULL TEXT  

Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study
Martel et al.
BMJ 2005;330:230.
ABSTRACT | FULL TEXT  

Impact of Concurrent Medication Use on Statin Adherence and Refill Persistence
Grant et al.
Arch Intern Med 2004;164:2343-2348.
ABSTRACT | FULL TEXT  

Mevalonate Promotes the Growth of Tumors Derived from Human Cancer Cells in Vivo and Stimulates Proliferation in Vitro with Enhanced Cyclin-dependent Kinase-2 Activity
Duncan et al.
J. Biol. Chem. 2004;279:33079-33084.
ABSTRACT | FULL TEXT  

Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge
Butler et al.
J Am Coll Cardiol 2004;43:2036-2043.
ABSTRACT | FULL TEXT  

Comply With Us: Improving Medication Adherence
Tabor and Lopez
Journal of Pharmacy Practice 2004;17:167-181.
ABSTRACT  

A Systematic Review of Adherence With Medications for Diabetes
Cramer
Diabetes Care 2004;27:1218-1224.
ABSTRACT | FULL TEXT  

Measurement, Correlates, and Health Outcomes of Medication Adherence Among Seniors
Vik et al.
The Annals of Pharmacotherapy 2004;38:303-312.
ABSTRACT | FULL TEXT  

Lipid-Lowering Drugs and the Risk of Depression and Suicidal Behavior
Yang et al.
Arch Intern Med 2003;163:1926-1932.
ABSTRACT | FULL TEXT  

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program
Menzin et al.
Psychiatr. Serv. 2003;54:719-723.
ABSTRACT | FULL TEXT  

Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer
Partridge et al.
JCO 2003;21:602-606.
ABSTRACT | FULL TEXT  

Why Aren't Lower, Effective, OTC Doses Available Earlier by Prescription?
Cohen
The Annals of Pharmacotherapy 2003;37:136-142.
ABSTRACT | FULL TEXT  

Outpatient adherence to beta-blocker therapy after acute myocardial infarction
Butler et al.
J Am Coll Cardiol 2002;40:1589-1595.
ABSTRACT | FULL TEXT  

Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study
Wei et al.
Heart 2002;88:229-233.
ABSTRACT | FULL TEXT  

Effect of partial compliance on cardiovascular medication effectiveness
Cramer
Heart 2002;88:203-206.
FULL TEXT  

Long-term Persistence in Use of Statin Therapy in Elderly Patients
Benner et al.
JAMA 2002;288:455-461.
ABSTRACT | FULL TEXT  

Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes
Jackevicius et al.
JAMA 2002;288:462-467.
ABSTRACT | FULL TEXT  

Elderly Patients' Adherence to Statin Therapy
Applegate
JAMA 2002;288:495-497.
FULL TEXT  

Adherence to Therapy With Oral Antineoplastic Agents
Partridge et al.
JNCI J Natl Cancer Inst 2002;94:652-661.
ABSTRACT | FULL TEXT  

Disparities in the Diagnosis and Pharmacologic Treatment of High Serum Cholesterol by Race and Ethnicity: Data From the Third National Health and Nutrition Examination Survey
Nelson et al.
Arch Intern Med 2002;162:929-935.
ABSTRACT | FULL TEXT  

Improving Drug Use in Elderly Patients: Getting to the Next Level
Avorn
JAMA 2001;286:2866-2868.
FULL TEXT  

Supplemental Insurance and Use of Effective Cardiovascular Drugs Among Elderly Medicare Beneficiaries With Coronary Heart Disease
Federman et al.
JAMA 2001;286:1732-1739.
ABSTRACT | FULL TEXT  

Use of Statins and the Subsequent Development of Deep Vein Thrombosis
Ray et al.
Arch Intern Med 2001;161:1405-1410.
ABSTRACT | FULL TEXT  

Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events
Cohen
Arch Intern Med 2001;161:957-964.
ABSTRACT | FULL TEXT  

Use of the Statins in Patients After Acute Myocardial Infarction: Does Evidence Change Practice?
Jackevicius et al.
Arch Intern Med 2001;161:183-188.
ABSTRACT | FULL TEXT  

Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial
Sniderman et al.
CMAJ 2001;164:44-47.
FULL TEXT  

Potential Clinical and Economic Effects of Homocyst(e)ine Lowering
Nallamothu et al.
Arch Intern Med 2000;160:3406-3412.
ABSTRACT | FULL TEXT  

Treating dyslipidaemia in primary care
Monkman
BMJ 2000;321:1299-1300.
FULL TEXT  

Enhancing Drug Compliance in Lipid-Lowering Treatment
LaRosa and LaRosa
Arch Fam Med 2000;9:1169-1175.
ABSTRACT | FULL TEXT  

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study
Blais et al.
Arch Intern Med 2000;160:2363-2368.
ABSTRACT | FULL TEXT  

Reliability of Self-reported Blood Pressure Measurements
Johnson et al.
Arch Intern Med 1999;159:2689-2693.
ABSTRACT | FULL TEXT  

Is Cholesterol a Risk Factor for Stroke?: No
Landau
Arch Neurol 1999;56:1521-1524.
FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; B. Guidelines for Determining Whether a Drug Is Exerting (More Than) a Class Effect
McAlister et al.
JAMA 1999;282:1371-1377.
FULL TEXT  

Direct-to-Consumer Prescription Drug Advertising Builds Bridges Between Patients and Physicians
Holmer
JAMA 1999;281:380-382.
FULL TEXT  

The Emerging Epidemic of Atherosclerosis: Call for Papers
Winker
JAMA 1999;281:84-85.
FULL TEXT  

Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish et al.
JAMA 1998;280:2001-2007.
ABSTRACT | FULL TEXT  

We Prescribe Medications, But Do Older Patients Take Them?
JWatch Women's Health 1998;1998:6-6.
FULL TEXT  

How Long Do Patients Stay with Lipid-Lowering Medications?
Journal Watch Cardiology 1998;1998:6-6.
FULL TEXT  

Poor Compliance with Lipid-Lowering Medications
JWatch General 1998;1998:6-6.
FULL TEXT